title: Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery.
abstract: OBJECTIVE
  Development of multifunctional and well-dispersed hollow mesoporous silica nanoparticles (HMSNs) for tumor vasculature targeted drug delivery and PET imaging.
  
  
  METHODS
  Amine functionalized HMSNs (150-250 nm) were conjugated with a macrocyclic chelator, (S)-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triaceticacid (NOTA), PEGylated and loaded with antiangiogenesis drug, Sunitinib. Cyclo(Arg-Gly-Asp-D-Tyr-Lys) (cRGDyK) peptide was attached to the nanoconjugate and radiolabeled with (64)Cu for PET imaging.
  
  
  RESULTS
  (64)Cu-NOTA-HMSN-PEG-cRGDyK exhibited integrin-specific uptake both in vitro and in vivo. PET results indicated approximately 8% ID/g uptake of targeted nanoconjugates in U87MG tumors, which correlated well with ex vivo and histological analyses. Enhanced tumor-targeted delivery of sunitinib was also observed.
  
  
  CONCLUSIONS
  We successfully developed tumor vasculature targeted HMSNs for PET imaging and image-guided drug delivery.
authors.affiliation: Department of Radiology, University of Wisconsin-Madison, WI 53792-3252, USA.
authors.forename: Rubel
authors.initials: R
authors.lastname: Chakravarty
authors.forename: Shreya
authors.initials: S
authors.lastname: Goel
authors.forename: Hao
authors.initials: H
authors.lastname: Hong
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.forename: Hector F
authors.initials: HF
authors.lastname: Valdovinos
authors.forename: Reinier
authors.initials: R
authors.lastname: Hernandez
authors.forename: Todd E
authors.initials: TE
authors.lastname: Barnhart
authors.forename: Weibo
authors.initials: W
authors.lastname: Cai
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000818:Animals; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D006571:Heterocyclic Compounds / Q000737:chemistry; D006573:Heterocyclic Compounds, 1-Ring; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008819:Mice, Nude; D053758:Nanoparticles / Q000737:chemistry*; D009369:Neoplasms / Q000098:blood supply*; D010456:Peptides, Cyclic / Q000737:chemistry; D016062:Porosity; D049268:Positron-Emission Tomography / Q000379:methods*; D011758:Pyrroles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012822:Silicon Dioxide / Q000737:chemistry*; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D004337:Drug Carriers; D006571:Heterocyclic Compounds; D006573:Heterocyclic Compounds, 1-Ring; D007211:Indoles; D010456:Peptides, Cyclic; D011758:Pyrroles; C550210:cyclo(Arg-Gly-Asp-Tyr-Lys); C048993:1,4,7-triazacyclononane-N,N',N''-triacetic acid; D012822:Silicon Dioxide; D000077210:Sunitinib
keywords: PET; cancer; hollow mesoporous silica nanoparticles; image-guided drug delivery; positron emission tomography; theranostics